FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Chu, J ^a   Lauretti, E ^a   Meco, A Di ^a   Pratico D ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; FLAP protein; Tau protein; Transgenic animal models

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 2A; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN P35; QUIFLAPON; SERINE; TAU PROTEIN; THREONINE; ALOX5AP PROTEIN, MOUSE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; DLGH4 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; GUANYLATE KINASE; INDOLE DERIVATIVE; MAPT PROTEIN, MOUSE; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MTAP2 PROTEIN, MOUSE; QUINOLINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; IMMUNOREACTIVITY; IN VIVO STUDY; MEMORY DISORDER; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; ANIMAL; BRAIN; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; TRANSGENIC MOUSE;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; 5-LIPOXYGENASE-ACTIVATING PROTEINS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; GLYCOGEN SYNTHASE KINASE 3; GUANYLATE KINASE; INDOLES; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; QUINOLINES; TAU PROTEINS;

EID: 84890186200     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.106     Document Type: Article

References (24)

1. Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med 2013; 64: 367-383.
2. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alz Res 2010; 7: 656-664.
3. Chu J, Praticò D. 5-Lipoxygenase as an endogenous modulator of amyloid beta formation in vivo. Ann Neurol 2011; 69: 34-46.
4. Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007; 405: 379-395. (Pubitemid 47172035)
5. Chu J, Pratico D. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation 2012; 9: 127.
6. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depre M et al. The effect of MK-591, a novel 5-lipoxygenase-activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airways responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95: 42-51.
7. Joshi YB, Chu J, Pratico D. Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease. J Alz Dis 2012; 31: 167-176.
8. Chu J, Pratico D. 5-lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase 5. Neurobiol Aging 2013; 34: 1549-1554.
9. Joshi YB, Chu J, Praticò D. Knockout of 5Lipoxygenase prevents dexamethasoneinduced tau pathology in the 3xTg mice. Aging Cell 2013; 12: 706-771.
10. Giannopoulos PF, Chu J, Joshi YB, Sperow M, JG Li, Kirby LG et al. FLAP reduction ameliorates cognitive deficit, synaptic dysfunction and neuropathology in a mouse model of Alzheimer. Biol Psychiatry 2013; 74(5): 348-356.
11. Hernadez F, Avila J. Tauopathies. Cell Mol Life Sci 2007; 64: 2219-2233. (Pubitemid 47347961)
12. Geschwind DH. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 2003; 40: 457-460.
13. Chinnici CM, Yao Y, Praticò D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging 2007; 28: 1457-1462. (Pubitemid 47081230)
14. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. Adeno-Associated Virus-Mediated Brain Delivery of 5-Lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegen 2012; 7: 1.
15. Mandal AK, Skoch J, Bacskai BJ, Hyman BT, Christmas P, Miller D et al. The membrane organization of leukotriene synthesis. Proc Natl Acad Sci USA 2004; 101: 6587-6592. (Pubitemid 38586018)
16. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Léveillé C, Mancini JA et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343: 278-281.
17. Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 284.
18. Evans JF, Lévillé C, Mancini JA, Prasit P, Thérien M, Zamboni R et al. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol 1991; 40: 22-27.
19. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT et al. Crystal structure of inhibitor-bound human 5-Lipoxygenase-activating protein. Science 2007; 317: 510-512. (Pubitemid 47196114)
20. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde T, Kayed R et al. Triple transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421. (Pubitemid 36937044)
21. Lee MS, Tsai LH. Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheim Dis 2003; 5: 127-137.
22. Maldonato H, Ramirez E, Utreras E, Pando MF, Kettlum AM, Chiong M et al. Inhibition of cyclin-dependent kinase 5 but not glycogen synthase kinase 3? prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res 2011; 89: 1489-1498.
23. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ et al. Over-expression of glycogen synthase kinase 3 by inhibition of phosphoinositol-3 kinase and protein C leads to hyperphosphorylation of tau and impaired spatial memory. J Neurochem 2003; 87: 1333-1344. (Pubitemid 38020568)
24. Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. 5-Lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol 2012; 72: 442-454.